I am a
Home I AM A Search Login

Papers of the Week


Papers: 22 Oct 2022 - 28 Oct 2022


Pharmacology/Drug Development


2022 Oct 27


Br J Clin Pharmacol

COVID-19 restrictions and the incidence and prevalence of prescription opioid use in Australia – a nation-wide study.

Authors

Jung M, Lukose D, Nielsen S, Bell SJ, Webb GI, Ilomäki J
Br J Clin Pharmacol. 2022 Oct 27.
PMID: 36301837.

Abstract

The COVID-19 pandemic has disrupted seeking and delivery of healthcare. Different Australian jurisdictions implemented different COVID-19 restrictions. We used Australian national pharmacy dispensing data to conduct interrupted time series analyses to examine the incidence and prevalence of opioid dispensing in different jurisdictions. Following nationwide COVID-19 restrictions, the incidence dropped by -0.40 [-0.50, -0.31], -0.33 [-0.46, -0.21] and -0.21 [-0.37, -0.04] /1000 people/week and prevalence dropped by -0.85 [-1.39, -0.31], -0.54 [-1.01, -0.07] and -0.62 [-0.99, -0.25] /1000 people/week in Victoria, New South Wales and other jurisdictions, respectively. Incidence and prevalence increased by 0.29 [0.13, 0.44] and 0.72 [0.11, 1.33] /1000 people/week, respectively in Victoria post-lockdown; no significant changes were observed in other jurisdictions. No significant changes were observed in the initiation of long-term opioid use in any jurisdictions. More stringent restrictions coincided with more pronounced reductions in overall opioid initiation, but initiation of long-term opioid use did not change.